Does Ambetter cover Wegovy? And Zepbound?

The Wegovy policy gives weight management its own numbered section. Then it refuses it in one sentence. "Use of Wegovy for the treatment of weight management is a benefit exclusion and will not be authorized." The approval duration for that section reads "Not applicable." The sentence runs twice, once under Initial Approval Criteria and once under Continued Therapy. So a member already on the drug through another payer has no way to keep it either. This is a benefit exclusion, not a clinical denial. BMI, other conditions and paperwork do not change it.

Source: Ambetter policy CP.PMN.295. Centene's own policy PDF at ambetterhealth.com, all 13 pages, read in full.

The Zepbound policy is built the same way. It carries the same sentence. "Use of Zepbound for the treatment of weight management is a benefit exclusion and will not be authorized." Its approval duration reads "Not applicable." That sentence runs under both Initial Approval Criteria and Continued Therapy. Ambetter has also said this to members in plain words. Ambetter from Arkansas Health and Wellness sent a member notice on November 21 2025, titled GLP-1 Medications: Coverage Exclusions for Weight Loss Treatment. The notice says Ambetter does not now cover GLP-1s prescribed only for weight management. It says the drugs stay covered for type 2 diabetes. That notice covers the Arkansas plan.

Source: Ambetter policy CP.PMN.298. Centene's own policy PDF, all 9 pages, read in full.

This is one of two Wegovy routes that survive the weight-management exclusion. The policy is strict about which heart or artery history counts. It also wants six months in a weight loss program a doctor directs, which is paperwork here, because weight loss is not the approved use. For Illinois marketplace requests, the policy notes that the diabetes step stopped applying on January 1 2026, under Illinois HB 5395.

What the prior authorization needs:

• Age 18 or older
• Prescriber attestation that the member is currently receiving cardiovascular standard of care management
• Actively enrolled in a physician-directed weight loss program for at least 6 months, and continuing in it while on Wegovy
• Documentation of baseline body weight in kg
• Not prescribed with another semaglutide product or any other GLP-1 receptor agonist
• The requested dose follows the label escalation schedule, ending at 2.4 mg once weekly for the injection or 25 mg per day for the tablet

Source: Ambetter policy CP.PMN.295. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full).

The FDA has approved the Wegovy shot for MASH, a liver disease, once fibrosis is moderate to advanced and the liver is not yet scarred to cirrhosis. Centene wrote a route for it. The policy takes either a biopsy, or a blood test paired with an imaging test. For blood it names FIB-4, the NAFLD fibrosis score and the enhanced liver fibrosis test. For imaging it names three: transient elastography, magnetic resonance elastography and MRI-PDFF. The policy notes that continued FDA approval for this use may depend on a confirmatory trial.

What the prior authorization needs:

• Age 18 or older
• Request is for Wegovy injection, not the tablet
• Prescribed by or in consultation with a hepatologist or gastroenterologist
• Stage F2 or F3 fibrosis confirmed by a liver biopsy within the last 3 years, or by both a serum-based assessment and an imaging-based assessment within the last 6 months
• Actively enrolled in a physician-directed weight loss program for at least 6 months and continuing in it
• Prescriber attestation of standard of care management for related conditions including type 2 diabetes, dyslipidemia and hypertension
• Not prescribed with Rezdiffra, another semaglutide product, or any other GLP-1 receptor agonist

Source: Ambetter policy CP.PMN.295. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full).

Sleep apnea is the one route to Zepbound on an Ambetter marketplace plan outside California. The PAP rule is written as an either-or, not a required trial. A member who cannot tolerate PAP is not shut out, but the request has to say which branch applies. Weight loss alone does not renew it. The file also needs a sleep measurement or a validated symptom score.

What the prior authorization needs:

• Age 18 or older
• No central or mixed sleep apnea
• Either a documented history of non-adherence to positive airway pressure therapy, or Zepbound prescribed alongside PAP therapy unless PAP is contraindicated or caused significant adverse effects
• Actively enrolled in a physician-directed weight loss program for at least 6 months and continuing in it
• Documentation of baseline body weight in kg
• Not prescribed with another tirzepatide product or any other GLP-1 receptor agonist
• Dose follows the label escalation schedule to a maximum of 15 mg once weekly, one pen or vial per week

Source: Ambetter policy CP.PMN.298. Centene's own policy PDF at ambetterhealth.com, read in full. Lower confidence: the policy file would not open at the payer's own address, so the policy number and rules were checked against a second source.

California is where the Centene answer flips. The Ambetter From Health Net Drug List for 2026 asks its own question and answers it. "Are Weight loss drugs covered? Most plans do cover weight loss medications after prior authorization has been approved." It then lists them. Wegovy, Wegovy Tablets, Zepbound and liraglutide (Saxenda) are on that list. So are Contrave, Qsymia, phentermine and orlistat. The rules come from the Health Net of California policies, not the Centene marketplace ones. Both carry a BMI table with a Marketplace row of its own, set at BMI 40 or higher. Both open with the same caution. Check the member's benefits for weight loss drug coverage. Some large groups set a different BMI. Some PPO plans may have no coverage. Compounded medications and samples are excluded. The Zepbound policy adds a grandfathering rule. A member already approved at a lower threshold keeps it, unless therapy lapses for more than 90 days.

What the prior authorization needs:

• Active participation in a Health Net approved weight loss program such as Weight Watchers or Active&Fit, or a prescriber-recommended lifestyle plan, for at least 6 months before starting the drug
• Agreement to stay in that program during treatment
• Documentation of current height and body weight to calculate BMI within the last 30 days
• Not prescribed with another GLP-1 or GIP/GLP-1 receptor agonist
• For Zepbound, age 18 or older, planned follow-up visits, and a dose not exceeding 15 mg once weekly
• For Zepbound, a request for the pre-filled single-use pen requires the member to use the KwikPen formulation

Source: Ambetter policy HNCA.CP.CPA.352 (Wegovy) and HNCA.CP.CPA.359 (Zepbound). The Health Net of California policy PDF at healthnet.com, all 20 pages, read in full.

The California sleep-apnea route sets a harder PAP test. The marketplace policy takes a written history of not sticking with PAP. Health Net wants more than that. It wants a failure while the member did stick with it, and it measures that in hours and nights. Or it wants evidence that PAP was never an option. It also caps the dose at 10 mg a week for sleep apnea, against 15 mg for weight management. And it wants the sleep study to be recent, not merely on file.

What the prior authorization needs:

• Age 18 or older
• No central or mixed sleep apnea
• Either continued OSA symptoms despite adherence to positive airway pressure therapy, where adherence means at least 4 hours per night on at least 70 percent of nights, or documentation that the member is not a candidate for PAP
• Active participation in a Health Net approved weight loss program or prescriber-recommended lifestyle plan for at least 6 months before starting, and continuing during treatment
• Documentation of baseline body weight within the last 30 days
• Dose does not exceed 10 mg once weekly
• A request for the pre-filled single-use pen requires the member to use the KwikPen formulation

Source: Ambetter policy HNCA.CP.CPA.359. Official Health Net of California clinical policy PDF published at healthnet.com (downloaded and read in full, 17 pages).

We read six 2026 Ambetter drug lists, all in force on January 1 2026, across Centene's largest marketplace states. None of them lists either drug on this page. That fits the clinical policies, but it does not prove the same thing. The drug lists set the limits of their own authority up front. One line reads: "the Formulary is not meant to be a complete list of the drugs covered under your prescription benefit". Another reads: "Specific prescription benefit plan designs may not cover certain products or categories, regardless of their appearance in this document." So an approved sleep-apnea or cardiovascular request runs through the non-formulary route instead. The documents give that route 24 hours for urgent requests, and 72 hours otherwise, unless state law is faster.

What the prior authorization needs:

• Wegovy, Zepbound, Saxenda and tirzepatide appear nowhere on the 2026 formularies for Florida, Texas, Georgia, North Carolina, Tennessee or New York
• The listed anti-obesity drugs on all six are phentermine hcl capsules and phendimetrazine tartrate tablets, both coded PA
• Ozempic, Rybelsus and Trulicity are listed for diabetes at Tier 2 with prior authorization and quantity limits
• Absence from the drug list is not by itself a coverage decision, because the formularies say they are not complete lists
• A drug approved through the non-formulary pathway is paid at Tier 3 under the documents' own tier key

Source: Ambetter from Sunshine Health 2026 Formulary, effective January 1 2026, document code AMB25-FL-C-00023, formulary introduction and the ADHD/anti-narcolepsy/anti-obesity/anorexiants section. Ambetter's own 2026 drug list PDF.